Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression ...

Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as ...

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

The Sydney-based oncology company revealed that NDL2 is designed to eliminate nuclear PD-L1, which Kazia identified as a previously unrecognized driver of immunotherapy resistance and metastatic ...

Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease.

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research ...

A proposed model illustrating how tumor cells release PD-L1-containing small extracellular vesicles (sEVs) that suppress ...

DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ResearchAndMarkets ...

PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...